This article is more than 5 years old. Information may no longer be current.
Hydroxychloroquine not linked with hemolytic anemia in patients with G6PD deficiency
Click Here to Manage Email Alerts
Among glucose-6-phosphate dehydrogenase-deficient patients with rheumatic disease, hydroxychloroquine was not linked with hemolytic anemia, according to a recently published analysis.
Samya Mohammad, DO, from Duke University Medical Center, and colleagues reviewed 275 patients, of which 32% had lupus; 29% had rheumatoid arthritis; 14% had inflammatory arthritis; and 4% were glucose-6-phosphate dehydrogenase (G6PD)-deficient. Overall, nearly half of the patients in the study (46%) were African American and all patients with G6PD-deficiency were African American.
Only two G6PD-deficient patients had hemolysis while not undergoing hydroxychloroquine therapy. In addition, there were no hemolysis episodes in the 11 G6PD-deficient patients.
Researchers reported this was the largest United States study of G6PD deficiency in patients undergoing hydroxychloroquine for rheumatic disease. – by Will A. Offit
Disclosure : Researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts